BioVie updates pipeline; plans Phase 2b PD trial summer 2024, delays AD Phase 3 to 2025

BIOVIE INC.

Raised $18.8M net ($21M gross) in equity financing to fund near-term priorities.
Phase 2b monotherapy trial of NE3107 in Parkinson's planned for late summer 2024; 100–150 patients.
Phase 3 Alzheimer's trial postponed to early 2025 to use once-daily NE3107 formulation.
BIV201 Phase 3 in ascites delayed pending partnership; FDA guidance received.
Previous NE3107 data showed 68% slowing on CDR-SB in AD and improved non-motor symptoms in PD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.